Oxford BioDynamics Plc (AIM:OBD)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 14.79M +136.0% |
| Revenue (ttm) | 1.20M +33.4% |
| Net Income | -9.87M |
| EPS | -0.00 |
| Shares Out | 13.44B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,876,207 |
| Open | 0.1000 |
| Previous Close | 0.1025 |
| Day's Range | 0.1000 - 0.1488 |
| 52-Week Range | 0.0800 - 0.3400 |
| Beta | -0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 16, 2026 |
About Oxford BioDynamics
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its p... [Read more]
Financial Performance
In fiscal year 2025, Oxford BioDynamics's revenue was 1.10 million, an increase of 72.17% compared to the previous year's 636,000. Losses were -11.15 million, -3.58% less than in 2024.
Financial StatementsNews
Oxford Biodynamics to present on its line of EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA.
OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on t...
Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy
OXFORD, England--(BUSINESS WIRE)-- #EpiSwitch--Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medici...